

ForPatients

by Roche

Schizophrenia

A Trial of the Efficacy and the Safety of RO6889450 vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder

Trial Status
Completed

Trial Runs In
4 Countries

Trial Identifier
NCT04512066 BP41743

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This study will investigate the efficacy and safety of RO6889450 as monotherapy in participants experiencing an acute exacerbation of symptoms of schizophrenia or schizoaffective disorder.

Hoffmann-La Roche
Sponsor

Phase 2
Phase

NCT04512066 BP41743
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>=18 Years & <= 45 Years

Healthy Volunteers
No
